SensPD Overview
SensPD develops an objective way to detect autism at a very early developmental stage, based on a physiological marker. The company uses Oto-Acoustic-Emission (OAE) devices, used in every hospital in the western world to screen for hearing issues, with IP protected changes to measure the sensory perception system performance and thus detect autism. SensPD cost effective solution is objective, model based, non-invasive (it is like a hearing test), easy and simple. It only takes a few minutes. The company's mission is to make sure that all newborns are properly tested and no family has to deal with the fear and worry of late autism detection ever again.
Latest News
growth-positive
Worldwide Business with kathy ireland®: See SensPD Introduce Their Revolutionary Method to Detect Autism at Birth
SensPD, a company based in Tel Aviv, Israel, is developing a technology to detect autism shortly after birth. Their mission is to ensure that all newborn babies are properly tested for autism so that early interventions can be provided. SensPD uses a physiological marker to objectively detect autism, rather than relying on behavioral observations. The screening test is simple and non-invasive, utilizing the sense of hearing to measure sensory perception. The results are then sent to the cloud for analysis. SensPD aims to be the main screening test for autism right after birth, with the goal of improving the lives of affected children from the start. The article features an exclusive interview with SensPDs Founder and Research Leader, Raffi Rembrand, and CEO and Co-Founder, Maayan Shahar.
Customers
growth-positive
3 Recent Israeli-Led Breakthrough Discoveries In Autism Research
Israeli researchers and companies are making groundbreaking developments in autism research. One Israeli company, SensPD, has developed a non-invasive diagnostic test that can screen newborns and infants for signs of autism. Another development is the use of medical cannabis, specifically cannabidiol (CBD), as an alternative treatment for autism. A study conducted in Israel showed significant improvements in symptoms such as self-injury, hyperactivity, and sleep problems after using CBD. Additionally, a study led by an Israeli professor found that women who take folic acid supplements and multivitamins before and during pregnancy have a reduced risk of having a child with autism.
Customers
growth-positive
SensPD Enters its First Round of Funding to Launch its Breakthrough Software Technology for the Early Detection of Autism in Newborns
SensPD, an Israeli start-up, aims to revolutionize the digital health market with its method for early objective detection of autism in newborns. The company uses Oto Acoustic Emission (OAE) devices to diagnose the brainstems response through vocal stimuli. SensPD is currently in clinical trials and plans to launch its product on a market-wide scale by the end of 2019. The company is seeking investors to support its go-to-market launch set for late 2018. SensPD has a solid advisory board and management team, and its market is estimated to be over $1 billion.
InvestmentExpand
growth-positive
Israeli dad shows how newborns can be screened for autism
SensPD, a startup founded by Raphael Rembrand, is developing a noninvasive diagnostic process to screen newborns for signs of autism. The process uses the same instrument currently used to test infants hearing and measures otoacoustic emissions as an indicator of the babys overall sensory perception. SensPD aims to detect autism earlier, allowing for early intervention and better outcomes. The company is ready for clinical trials and has enlisted hospitals in the US and Israel for the studies. SensPDs business model is to charge for the database analysis rather than the screening test. The founder has self-funded the company and won a $100,000 prize in a competition. SensPD is seeking funding to support its clinical studies.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $280K |
| Last funding | $180K |
| Stage | Pre-Funding |
| Rounds | 3 |
| Investors | 0 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | www.senspd.com |
Locations
Kiryat Tiv'on, Israel
Photos & Videos
2 item(s)
SensPD Business
Business models
B2B, B2C
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesDiagnostics DevicesTarget Customer
Healthcare & Life SciencesHealthcareLaboratoriesProvidersCore Technology
SensingAcousticsTags (10)
hospitalsmedical-technologiesparentsbabiesnon-invasiveearly-detectionchildrendiagnosticsmedical-devicesautismGeographic Markets
GlobalSensPD Financials
$280K
Total funding
—
Capital raised
$180K
Last funding
Pre-Funding
Funding stage
3
Total rounds
0
Investors
Non-Equity Funding
GrantEvent
Jun 2018
$180K
European Commission, WeWork Creator Awards
GrantEvent
Jun 2017
$100K
Merage foundation
GrantEvent
Nov 2016
Undisclosed
MassChallenge
SensPD Lifecycle
All Events
GrantEvent
Jun 2018
$180K
European Commission, WeWork Creator Awards
GrantEvent
Jun 2017
$100K
Merage foundation
GrantEvent
Nov 2016
Undisclosed
MassChallenge
SensPD News
4 articles
growth-positive
Worldwide Business with kathy ireland®: See SensPD Introduce Their Revolutionary Method to Detect Autism at Birth
SensPD, a company based in Tel Aviv, Israel, is developing a technology to detect autism shortly after birth. Their mission is to ensure that all newborn babies are properly tested for autism so that early interventions can be provided. SensPD uses a physiological marker to objectively detect autism, rather than relying on behavioral observations. The screening test is simple and non-invasive, utilizing the sense of hearing to measure sensory perception. The results are then sent to the cloud for analysis. SensPD aims to be the main screening test for autism right after birth, with the goal of improving the lives of affected children from the start. The article features an exclusive interview with SensPDs Founder and Research Leader, Raffi Rembrand, and CEO and Co-Founder, Maayan Shahar.
Customers
growth-positive
3 Recent Israeli-Led Breakthrough Discoveries In Autism Research
Israeli researchers and companies are making groundbreaking developments in autism research. One Israeli company, SensPD, has developed a non-invasive diagnostic test that can screen newborns and infants for signs of autism. Another development is the use of medical cannabis, specifically cannabidiol (CBD), as an alternative treatment for autism. A study conducted in Israel showed significant improvements in symptoms such as self-injury, hyperactivity, and sleep problems after using CBD. Additionally, a study led by an Israeli professor found that women who take folic acid supplements and multivitamins before and during pregnancy have a reduced risk of having a child with autism.
Customers
growth-positive
SensPD Enters its First Round of Funding to Launch its Breakthrough Software Technology for the Early Detection of Autism in Newborns
SensPD, an Israeli start-up, aims to revolutionize the digital health market with its method for early objective detection of autism in newborns. The company uses Oto Acoustic Emission (OAE) devices to diagnose the brainstems response through vocal stimuli. SensPD is currently in clinical trials and plans to launch its product on a market-wide scale by the end of 2019. The company is seeking investors to support its go-to-market launch set for late 2018. SensPD has a solid advisory board and management team, and its market is estimated to be over $1 billion.
InvestmentExpand
growth-positive
Israeli dad shows how newborns can be screened for autism
SensPD, a startup founded by Raphael Rembrand, is developing a noninvasive diagnostic process to screen newborns for signs of autism. The process uses the same instrument currently used to test infants hearing and measures otoacoustic emissions as an indicator of the babys overall sensory perception. SensPD aims to detect autism earlier, allowing for early intervention and better outcomes. The company is ready for clinical trials and has enlisted hospitals in the US and Israel for the studies. SensPDs business model is to charge for the database analysis rather than the screening test. The founder has self-funded the company and won a $100,000 prize in a competition. SensPD is seeking funding to support its clinical studies.
Customers
SensPD Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 1 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
SensPD Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | funding rounds, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515577773 |
| Crunchbase | senspd-ltd |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-08-17T00:00:00.000Z |
| Created | 2016-05-01T00:00:00.000Z |